REG-Arix Bioscience PLC Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock

Arix BioscienceAnnouncement

10/11/2023 08:00

============

   Arix Bioscience PLC (ARIX)
   Portfolio Company Aura Biosciences Announces Closing of $99 million Public
   Offering of Common Stock

   10-Nov-2023 / 08:00 GMT/BST

   ══════════════════════════════════════════════════════════════════════════

                                        

                              Arix Bioscience plc

                                        

   Portfolio Company Aura Biosciences Announces Closing of $99 million Public
                            Offering of Common Stock

                                        

   LONDON, 10 November 2023:  Arix Bioscience plc  (“Arix” or the  “Company”)
   (LSE: ARIX), a transatlantic venture capital company focused on  investing
   in breakthrough  biotechnology companies,  notes that  its Core  Portfolio
   company, Aura  Biosciences  (NASDAQ:  AURA) (“Aura”),  has  announced  the
   closing of its underwritten  public offering of  11,000,000 shares of  its
   common stock at a price to the public of $9.00 per share.

    

   The Company received net proceeds  from the Offering, after deducting  the
   underwriting discounts  and commissions  and estimated  offering  expenses
   payable by  the  Company,  of approximately  $92.6  million.  The  Company
   intends to  use the  net proceeds  from the  Offering, together  with  its
   existing cash, cash equivalents and  marketable securities to advance  the
   clinical development  of  belzupacap  sarotalocan  for  the  treatment  of
   choroidal melanoma and choroidal metastasis,  to develop the platform  and
   for general corporate purposes. The Company believes that the net proceeds
   from this offering, together with its existing cash, cash equivalents  and
   marketable securities, will enable it  to fund its operating expenses  and
   capital expenditure requirements into the second half of 2026.

    

   Arix holds 1,508,483  shares in Aura.  The holding value  of these  shares
   will continue to be determined by the market price of Aura’s shares.

    

   The full  text  from Aura’s  announcement  can  be accessed  on  the  Aura
   Biosciences website here:  1 https://ir.aurabiosciences.com/press-releases

    

                                      ENDS 

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 2 @arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil, Nick Johnson

   +44 (0)20 7250 1446

    3 arix@powerscourt-group.com

    

    

    

   About Arix Bioscience plc

   Arix Bioscience plc is a transatlantic venture capital company focused  on
   investing in  breakthrough  biotechnology  companies  around  cutting-edge
   advances in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise, and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  4 www.arixbioscience.com

    

   ══════════════════════════════════════════════════════════════════════════

   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  MSCM
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   283959
   EQS News ID:    1770215


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    5 fncls.ssp?fn=show_t_gif&application_id=1770215&application_name=news&site_id=refinitiv2

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=5c002e93d4b214c9735c1f5700b257e2&application_id=1770215&site_id=refinitiv2&application_name=news
   2. mailto:charlotte@arixbioscience.com
   3. mailto:arix@powerscourt-group.com
   4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1770215&site_id=refinitiv2&application_name=news


============